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In this study we examined pharmacokinetics, systemic exposure and sputum penetration of azithromycin (AZM) in CF patients on chronic
daily AZM therapy after changing to a once weekly dosing scheme.
Eight adult CF patients using AZM 500 mg/day were changed to a once weekly dose of 1000 mg during 3 months. Once per month
sputum and blood samples were collected. AZM was quantified in blood plasma and polymorphonuclear neutrophils.
The cumulative weekly dose was reduced with a factor of 3.5 (7×500 mg vs. 1×1000 mg weekly).This led to a reduction in area under
the curve (AUC±S.D.) with a factor of 2.5±0.8 in plasma, 2.8±0.9 in blood, 2.2±1.1 in PMNNs and to a reduction in average sputum
concentration with a factor of 3.0 (±1.5).
At 1000 mg once weekly reduced but still substantial concentrations were achieved in PMNNs and in sputum. Although not significant, a
tendency towards less than linear reduction was found. In order to calculate and propose an optimal dosing scheme we need to establish a
relation between exposure levels and clinical efficacy.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Azithromycin; Pharmacokinetics; Sputum; Penetration; Polymorphonuclear neutrophil; Once weekly dosing1. Introduction
Chronic use of azithromycin (AZM) reduces or stabilizes
clinical symptoms of airway inflammation associated with
chronic infection of Pseudomonas aeruginosa in patients
with cystic fibrosis (CF). Clinical studies demonstrating this
effect have been performed with different dosing schedules
ranging from 250 mg to 500 mg 3 times per week to 250 mg
once daily). All randomized controlled trials comparing
AZM with placebo have shown a significant advantage in
ΔFEV1 and a reduction in number of exacerbations in
patients on AZM [1–6].
We have previously reported pharmacokinetic data for
AZM after chronic administration of 500 mg daily. AZMwas⁎ Corresponding author. Fax: +31 0031703217156.
E-mail address: e.wilms@ahz.nl (E.B. Wilms).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.05.005quantified in plasma, blood, isolated polymorphonuclear
neutrophils (PMNNs) and sputum of 8 adult CF patients and
demonstrated an extended elimination t1/2 in plasma (102±
20 h), blood (180±68 h) and in PMNNs (289±166 h) [7]. In
bloodwe found aCmax of 2.01±0.74mg/l atTmax of 3±1.1 h of
which 1.44±0.69 mg/l (72%) was found in PMNNs. In sputum
the concentration was between 12 and 53 mg/l (immediately
after the last dose) and was still between 4 and 27 mg/l 10 days
after the last dose. On average, the concentration we found
in PMNNs was 2100 times the Cplasma 24 h after the last dose.
We concluded that accumulation in PMNNs is high and
that the t1/2 in PMNNs and in sputum is long enough (289 h)
to explore a dosing interval of 1 week, assuming a
relationship between concentration in PMNNs or sputum
and the clinical efficacy of AZM [7].
The key mode of action of AZM in CF patients remains
unclear. Both a sub-MIC anti Pseudomonas effect due to
interference with Pseudomonas biofilm formation or a non-ed by Elsevier B.V. All rights reserved.
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sized to lead to a reduction in decline of lung function [8–
11]. Several investigators have published results of in vitro
experiments towards the mode of action and the
corresponding concentrations of AZM. Tateda et al. found
inhibition of quorum sensing factor production at concentra-
tions of 2 mg/l in the P. aeruginosa strain PAO1 and a
reduction of the viability of P. aeruginosa after exposure of
48 h of AZM in a concentration of 0.5 mg/l [8,9]. Takeoka et
al. found a MIC of 100 mg/l towards both mucoid and non-
mucoid strains of P. aeruginosa. Moreover this study also
suggested an increase of P. aeruginosa phagocytosis by
PMNNs after exposure to sub MIC concentrations of AZM
[10].
The sputum levels we found in our previous study exceed
the levels at which quorum sensing signalling is reported to
be influenced but do not reach MIC levels towards P.
aeruginosa [7]. Based on our previous findings at a dose of
500 mg/day, we postulate that sputum levels will remain at a
level high enough to retain the proposed anti Pseudomonas
and/or anti-inflammatory activity during a dosing schedule
with an extended dosing interval.
The weekly dose selected in the current study was
primarily based on equivalence to the lowest cumulative
weekly dose administered in a randomized controlled trial
and secondly a weekly dose of 1000 mg is generally well
tolerated in other patient groups (i.e. prophylactic treatment
in HIV-infected patients and the treatment of Chlamidia
trachomatis infection) [12,13].
The primary aim of this study was to describe
pharmacokinetic data and exposure in blood, PMNNs and
sputum of a once weekly dosing schedule in CF patients
already on chronic once daily AZM treatment and to
compare data of both dosing schedules. A secondary target
is to describe the tolerability of the once weekly dosing
schedule. The clinical efficacy of such a change in dosing
regimen was not a part of this study.
2. Patients and methods
2.1. Patients
8 adult patients with CF were recruited from the Adult
Cystic Fibrosis Centre at the Haga Teaching Hospital.
Patients receiving AZM 500 mg once daily for at least
35 days with chronic P. aeruginosa infection (confirmed
with at least 2 positive cultures in the last 6 months) were
eligible to the study. The study protocol was approved by the
regional medical ethical review board and patients gave
written informed consent prior to study participation.
2.2. Drug administration and sampling
AZM was administered as 500 mg tablets (Zithromax®
tablets 500 mg, Pfizer, Capelle a/d IJssel, The Netherlands)
once daily for at least 35 days prior to recruitment in the onceweekly study. Upon enrolment, blood samples were
collected immediately before (C0) and 3 h after (C3) the
final dose of 500 mg AZM once daily. Sputum was collected
during 24 h. Hereafter the dosing regimen was changed to
1000 mg once weekly and continued throughout the 3-month
study period. Blood and sputum samples were collected after
1, 2 and 3 months. Spontaneously produced sputum was
collected during a 24-h period preceding the blood
collection. After the 3-month study, patients returned to
500 mg AZM daily.
At each time point blood samples were collected
immediately before the weekly dose of AZM and 3 h after
dosing. AZM was given in the form of two 500 mg tablets
which were swallowed with a glass of water.
Venous lithium-heparinized blood (119 IU li-heparin/
7-ml tube, Vacutainer™ Becton-Dickinson, Alphen a/d Rijn,
The Netherlands) samples were collected at each time point.
Adverse effects were documented at each visit as a
measure of drug tolerability.
2.3. Isolation procedure of polymorphonuclear neutrophils
and bioanalysis of AZM
PMNNs were isolated from lithium-heparinized venous
blood samples. Before the separation a differential blood cell
count was made. To 6.0 ml of blood 6.0 ml of phosphate-
buffered saline (PBS; pH 7.4, Mallinckrodt-Baker, Deventer,
The Netherlands) was added. The diluted blood–PBS mixture
was transferred into a separation tube with a 6.0-ml layer of
Ficoll-Paque Plus® density separation medium (Amersham
Biosciences, Uppsala, Sweden) and centrifuged for 15 min
(1250 G) at 21 °C. The supernatant and Ficoll-Paque Plus®
layer were removed and the cell pellet with neutrophils and
erythrocytes was incubated during 15 min with 45 ml of NaCl
0.2% at 2–6 °C in order to lyse the erythrocytes. PMNNs were
isolated by centrifugation (5 min 465 G) and resuspended in
6.0 ml PBS. A differential cell count was performed to
determine the number of isolated neutrophils. After centrifu-
gation (5min 465 G) the supernatant was removed and the cell
pellet was kept at −30 °C until assay of AZM.
Detailed specifications and validation of the methodology
of cell isolation and AZM quantification in blood, plasma
and PMNNs are described elsewhere [14].
In brief, a high-performance liquid chromatographic
method with pre-column derivatization and fluorescence
detection was used for the quantification of AZM in blood,
plasma, isolated PMNNs and sputum. Clarithromycin
(CLM, Abbott, Queenborough, UK) was used as an internal
standard and AZM dihydrate salt (Pfizer Inc., New York,
USA) was used as reference. Pre-column derivatization was
performed using 9-fluorenylmethyloxycarbonyl-chloride
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Analytical
separation was carried out using a C18 column as station-
ary phase and a mixture of 760 ml acetonitrile (Merck,
Darmstadt, Germany) and 240 ml 0.02 M phosphate buffer
(0.65 g potassium dihydrogen phosphate (Merck, Darmstadt,
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hydroxide 10%) as mobile phase. Fluorometric detection of
the analytes was used for quantification (λexcitation=267 nm
and λemission=317 nm).
Calibration curves in plasma and blood (0–1.5 mg/l) were
used for determination in plasma and blood. A calibration
curve in water (0–9 mg/l) was used for determination in
sputum and the PMNN fraction.
Plasma, blood, PMNNs and sputum samples were kept at
−30 °C until determination. Quantification of AZM in PMNN
samples was performed after thawing and the addition of
distilledwater to a total volume of 1.2ml. AZMwas quantified
in duplicate in 0.5 ml aliquots in plasma, blood and PMNNs.
Sputum was homogenized by vortex mixing (after addition of
glass pearls) and a 50 μl and a 250 μl aliquot was diluted with
distilled water till 0.5 ml and extracted according to the
procedure described above. The two sample volumes were
used to assess homogeneity of the sputum sample.
The lower limit of quantitation of AZM was 0.042±
0.017 mg/l in plasma, 0.119±0.065 mg/l in blood and
0.072±0.036 mg/l in water. Linearity was assessed for
0–1.5 mg/l in plasma and blood and for 0–9 mg/l in water
[14].
Recovery and intra-assay variation (expressed as %CV)
from plasma at 0.635 mg/l AZM was 103.0% (n=6, %
CV=1.5%) and of 1.0 mg/l CLM was 100.0% (n=6, %
CV=0.8%). The recovery from blood of 0.635 mg/l AZM
was 94.5% (n=6, %CV=2.3%) and of 1.0 mg/l CLM was
99.4% (n=6, %CV=1.6%). Inter-assay variations at
0.635 mg/l (n=6) and 1.182 mg/l (n=5) in plasma were
2.2% and 2.8%, respectively. In blood the inter-assay
variations at 0.295 mg/l (n=6) and 0.739 mg/l (n=6) were
2.4% and 3.9%, respectively [14].
Intra-assay variation of the combined PMNN separation
procedure and AZM quantification was 4% (n=4) at
1.35 mg/l and 14% (n=4) at 0.61 mg/l [14].
2.4. Pharmacokinetic calculations
The concentration time points were processed with the
pharmacokinetic modeling program MW/Pharm version
3.50 (MediWare, Groningen, Netherlands) [15].Table 1
Pharmacokinetic data of AZM 500 mg/day and 1000 mg/week in 8 CF patients
Sample: Plasma Blood
Regimen: 500 mg/day 1000 mg/week 500 mg
C0 (mg/l) 0.09 (0.03) 0.023 (0.027) 0.56 (
C3 (mg/l) 0.35 (0.14) 0.77 (0.53) 1.30 (
Cmax estimated(mg/l) 0.35 (0.14) 1.10 (0.54) 1.31 (
Vd/F (l) 4790 (625) 4286 (1028) 1365 (
Cl/F (l/h) 45.7 (7.5) 37.0 (7.4) 5.7 (
AUC0–168 h (h mg/l) 38.5 (19) 15.2 (4.6) 130.0 (
t1/2β (h) 73.6 (9.9) 136 (164) 194 (
Values are average (S.D.); C=concentration; Vd=volume of distribution; F=bioa
absorption and distribution phase.For estimating pharmacokinetic parameters, the method
of D-optimal sampling time was chosen, adjusted to practice.
Based on the pharmacokinetic parameters determined in our
previous work, D-optimal sampling times were determined
according to the method of D'Argenio [7,16]. The sample
time points, immediately before dosing and 3 h after dosing
were planned during the nearest scheduled visit to the
outpatient clinic.
Pharmacokinetic parameters t1/2, Cl/F, Vd/F and Cmax for
individual subjects were estimated by fitting the model to the
data. We calculated the level of exposure per interval
expressed as area under the (concentration–time) curve
(AUC). AUC data were normalized to 7 days of exposure for
both dosing regimens. Average values with standard
deviation were calculated of t1/2, Cl/F, Vd/F and Cmax.
3. Results
3.1. Patients
Eight CF patients (4 male, 4 female) with a mean age of
29.3 years (range 22–47 years), mean weight of 61.5 kg
(range 51–84 kg) and a mean body mass index of 21.0 (range
17–24 kg/m2) participated in the study. All patients were
chronically infected with P. aeruginosa and had received
AZM 500 mg once daily for more than 35 days.
3.2. Tolerability
Six patients reported no change in side-effects. Two
patients experienced an increase in transient nausea starting
shortly after intake of 1000 mg AZM and lasting 3–6 h. One
of these patients continued the dosing schedule of 1000 mg
weekly. For the second patient the weekly dose was split in
500 mg once daily on 2 consecutive days during the 3rd
(last) month of the study. This patient's data of the 3rd month
were excluded from the pharmacokinetic calculations.
3.3. Pharmacokinetics of AZM
The AUC per week in plasma, whole blood and PMNNs
are summarized in Table 1. The individual sputumPMNNs
/day 1000 mg/week 500 mg/day 1000 mg/week
0.24) 0.26 (0.20) 0.72 (0.61) 0.31 (0.30)
0.47) 1.57 (0.92) 1.31 (0.76) 0.58 (0.52)
0.47) 2.15 (1.07) 1.31 (0.76) 1.31 (0.86)
298) 1820 (1714) 398 (89) 2025 (3088)
2.5) 5.1 (2.3) 12.1 (7.7) 6.6 (4.9)
51) 53 (29) 165.6 (106.7) 76.9 (30.0)
79) 254 (239) 32.7 (23.4) 180 (224)
vailability; Cl=clearance; AUC=area under the curve; t1/2β=half life after
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produce a sputum sample at the 3rd visit after 2 months.
In sputum we found an average concentration of 26.6 mg/
l (S.D.=15.6; min=12 mg/l, max=62 mg/l) at the dose of
500 mg/day. At the dose of 1000 mg AZM once weekly, we
found an average concentration of 9.6 mg/l (S.D.=7.1;
min=2.5 mg/l, max=20.9 mg/l) in sputum collected
between 144 and 168 h after dosing.
Calculated on a weekly basis we reduced the dose with a
factor of 3.5 (7×500 mg vs. 1×1000 mg weekly).This led to
a reduction in AUC (±S.D.) with a factor of 2.5±0.8 in
plasma, 2.8±0.9 in blood, 2.2±1.1 in PMNNs and to a
reduction in average sputum concentration with a factor of
3.0 (±1.5).
4. Discussion
This pharmacokinetic study was performed to obtain
pharmacokinetic data during a once weekly dosing schedule
of AZM in adult cystic fibrosis patients. Our main objective
was to describe the level of exposure in blood (expressed as
AUC) and the concentration in sputum. The results show
an almost linear relation between the dose and the AUC
in blood and the concentration in sputum. A weekly dose
of 1000 mg is related to a reduced but still substantial
concentration in sputum. The concentration in sputum is
remarkably stable during the 3 consecutive monthly visits.
Our pharmacokinetic parameters were based on the samples
drawn 2 and 3 months after start of once weekly dosing. On
the basis of the half life in sputum and PMNNs, we assumed
that a steady state equilibrium was not achieved within 5
times t1/2. In most patients, however, we see a stable con-
centration in sputum with little difference between the sam-
ples after 1, 2 and 3 months.
Although several dosing schemes with a lower weekly
dose have been investigated in CF (i.e. 250–500 mg 3 times
per week) our patients were still using 500 mg/day, a dose
level registered for chronic use in HIV infected patients [13].Fig. 1. Individual sputum concentrations of azithromycin (AZM) during dose regim
after 1, 2 and 3 months). AZM concentration was determined in spontaneously prod
AZM.In this study we intended to use a weekly equivalent for a
dose schedule which was proven effective in a randomized
clinical trial. We chose 1000 mg for the once weekly dose.
The lowest dose proven effective in a randomized clinical
trial was 250 mg 3 times weekly in patients b40 kg and
500 mg 3 times weekly in patients N40 kg. As all of our
patients were N40 kg, our dose per kg bodyweight per week
was lower than in the study of Saiman [4].
We found that 6/8 patients tolerated a change in dosing
regimen from 500 mg/day to 1000 mg once weekly without
change in adverse events. In two patients nausea was
increased. These results reflect the tolerability in patients
already tolerating 500 mg/day and cannot be extrapolated to
AZM-naïve patients.
We quantified AZM in sputum which was obtained by
spontaneous coughing up during 1 day. Compared to
samples obtained by bronchoalveolar lavage (BAL) our
method of sampling was less stressful for our patients and
correction for dilution was not necessary. On the contrary we
cannot exclude some dilution with saliva. AZM is excreted
in saliva but its concentrations are comparable to serum and
do not reach the concentrations we found in sputum, and
therefore hardly influences our findings [17].
Comparing the pharmacokinetic data before and after the
change in dosing regimen, a reduction in C0 in plasma, blood
and PMNNs was observed. The estimated Cmax was tripled
in plasma but remained similar in PMNNs. In PMNNs, the
C0 was reduced in the weekly regimen in accordance with
the expected t1/2 .
In all matrices an increase in t1/2 was found at weekly
dosing. We attributed this effect to the presence of a third
compartment which influences the terminal t1/2. In weekly
dosing the influence of a third compartment on the terminal
t1/2 is more pronounced than in once daily dosing and could
explain the increased t1/2 and decreased clearance. We
hypothesize that PMNNs act as a third compartment due to
their AZM accumulation and uptake and release character-
istics. In interpretation of t1/2 data we must keep in mind theen 1 (500 mg once-daily; day 1) and dose regimen 2 (1000 mg once-weekly;
uced sputum collected on the day before administration of the weekly dose of
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within 1× t1/2. For a more accurate determination of terminal
t1/2 sampling over 4–5× t1/2 would be necessary. We assume
that the t1/2 we determined reflects an underestimation of the
true terminal t1/2 which is extremely long due to uptake,
release and reuptake in neutrophils. These data agree with in
vitro studies which have demonstrated rapid uptake into
neutrophils and slow release from neutrophils [18].
In this study the level of systemic exposure was expressed
by the parameter AUC. Reducing the weekly dose with a
factor of 3.5 leads to the reduction in AUC with a factor of
2.5 in plasma, 2.8 in blood and 2.2 in PMNNs. Although
differences were not statistically significant, a trend towards
a less than linear reduction in AUC could be observed in all
the examined matrices.
This finding is comparable to the differences in exposure
level found by Amsden [19]. He compared administration of
1500 mg at once with 500 mg/day for 3 days. He found an
increase in AUC in serum which did not reach statistical
significance but tended towards a higher level of exposure
after a single dose [AUC0–∞ 1500 mg as a single dose:
13.1 mg h/l (3.02–20.6 mg h/l); as three 500-mg doses:
11.2 mg h/l (2.98–24.5 mg h/l)] [19].
These findings can be the result of the uptake, release and
reuptake characteristics of AZM which are more pronounced
at a longer dose interval as explained above.
Alternatively we hypothesize that these findings might be
caused by changes in bioavailability of AZM. In our
pharmacokinetic model, we assumed that the bioavailability
was identical during both dosing regimens. An increase in
bioavailability when AZM is given at the dose of 1000 mg,
however, could explain the relative increase of the AUC after
switching to 1000 mg weekly. An increase in bioavailability
could be caused by enzyme saturation of P-glycoprotein
(which acts as an efflux pump in intestinal cells) since AZM
is a substrate for P-glycoprotein [20].
This study demonstrates a mean reduction in sputum
concentration of AZM by a factor of 3.0 after conversion to
once weekly dosing, which is in the same magnitude as the
reduction in AUC plasma (factor of 2.5) and blood (factor of
2.8). This reduction occurred within the first month and
remained stable during the course of the study in 7 out of
8 patients. The variation in sputum concentration within these
7 subjects was remarkably low during the 3 monthly visits.
On the other hand, a substantial inter-individual variation
was observed which could not be related to any clinical
parameter or co-medication.
In 1 patient no stabilization in sputum concentration was
reached. In this patient the decline in sputum concentration
partially correlatedwith a decline in pre-doseAZMblood levels
which occurred in this patient after 2 months instead of direct
after the first month. We do not know whether this finding was
due to non adherence to the dosing scheme or to changes in
patient characteristics (resorption, sputum production).
We collected sputum samples on the day before dosing
1000 mg. These samples (C0) represent trough levels. Fromour previously reported data on sputum clearance of AZM
we can calculate that the concentration on day 1 will be 30–
40% higher compared to the concentration on days 5–10 [7].
Whether these sputum concentrations remain within the
therapeutically effective range for all patients remains to be
established.
These pharmacokinetic data can be seen in relationship
with the clinical results of a randomized clinical trial
comparing 250 mg AZM once daily and 1200 mg AZM
once weekly (S. Bell, personal communication). These
dosing schedules comprise a difference in cumulative
weekly dose with a factor of 1.5 (1750 mg vs. 1200 mg).
Taking our results into account, this will result in a reduction
in systemic exposure and in sputum concentration with a
factor of 1.5, or slightly less.
We conclude that a single dose of 1000 mg AZM weekly
is generally well tolerated by most CF patients. Although not
statistically significant there was a trend towards less than
linear reduction in systemic exposure. At 1000 mg once
weekly reduced but still substantial concentrations were
achieved in PMNNs and in sputum. In order to calculate and
propose an optimal dosing scheme we need to establish a
relation between exposure levels and clinical efficacy.
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